Ye Weiguo sold $129K of GYRE
Ye Weiguo (Chief Operating Officer) sold 20,918 shares of GYRE THERAPEUTICS, INC. (GYRE) at an average of $6.16 ($6.14–$6.21, $0.13M total) across 2 trades over 2026-06-09 to 2026-06-10.
How this was made
The 30-second read
Why it matters
The newest fact is the COO’s open-market sale amount, timing (June 9–10), and post-transaction holdings; it can marginally affect sentiment but does not, by itself, change fundamentals.
Market read
Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a material repricing without additional company catalysts.
What to watch
Check for clustering of insider sales across officers/directors and whether there are concurrent positive catalysts (trial updates, financing, partnerships) that could offset sentiment.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for GYRE Therapeutics.
Ticker impact
SEC Form 4 shows COO Ye Weiguo sold 20,918 shares of GYRE in open-market trades for ~$128.9K, leaving 700,000 shares.
Low near-term impact; any effect is likely sentiment-only unless follow-on selling or other catalysts emerge.
The disclosure is a primary-source Form 4, but it is an insider sale (not a buy), and the article provides no accompanying company-specific negative catalyst (e.g., guidance, trial failure, enforcement).
Market effects
No sector read-through; this is a single-company insider transaction with no stated operational/regulatory linkage.
None indicated.
None indicated.
Counterpoint
Insider sales can be planned for liquidity/tax and do not necessarily signal reduced confidence—especially since the filing notes no 10b5-1 plan but still reflects small, non-control-scale selling.
Key entities
- issuerGYRE THERAPEUTICS, INC.
Company whose insider transaction is disclosed on SEC Form 4.
- insiderYe Weiguo
Chief Operating Officer who sold 20,918 shares in open-market trades.